Edition:
United States

Bio Rad Laboratories Inc (BIOb.N)

BIOb.N on New York Stock Exchange

290.50USD
22 May 2018
Change (% chg)

-- (--)
Prev Close
$290.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
183
52-wk High
$290.80
52-wk Low
$222.50

Chart for

About

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $8,641.95
Shares Outstanding(Mil.): 29.80
Dividend: --
Yield (%): --

Financials

  BIOb.N Industry Sector
P/E (TTM): 12.51 39.23 32.60
EPS (TTM): 23.09 -- --
ROI: 14.97 14.36 12.74
ROE: 19.36 17.21 14.66

BRIEF-Bio-Rad Q1 Earnings Per Share $21.77

* Q1 EARNINGS PER SHARE VIEW $1.07 -- THOMSON REUTERS I/B/E/S

May 08 2018

BRIEF-Bio Rad Laboratories Says CEO Norman Schwartz's 2017 Total Compensation Was $5.4 Mln Vs $4.9 Mln In 2016

* BIO RAD LABORATORIES INC SAYS CEO NORMAN SCHWARTZ'S 2017 TOTAL COMPENSATION WAS $5.4 MILLION VERSUS $4.9 MILLION IN 2016 – SEC FILING Source text: (https://bit.ly/2KCpD6p) Further company coverage:

May 04 2018

BRIEF-Bio Rad Laboratories Says KPMG Notified Senior Management It Required More Time To Complete Audit Of 2017 Financial Statements

* BIO RAD LABORATORIES - KPMG NOTIFIED SENIOR MANAGEMENT IT REQUIRED MORE TIME TO COMPLETE AUDIT OF 2017 FINANCIAL STATEMENTS - SEC FILING

Mar 16 2018

BRIEF-Bio Rad Laboratories Files For Non-Timely 10-K - SEC Filing

* BIO RAD LABORATORIES FILES FOR NON-TIMELY 10-K - SEC FILING Source text (http://bit.ly/2FeZn29) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 02 2018

BRIEF-Bio-Rad Q4 Earnings Per Share $2.32

* BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Bio-Rad Gains Additional U.S. FDA Clearances

* BIO-RAD GAINS ADDITIONAL U.S. FDA CLEARANCES FOR BLOOD TYPING PRODUCTS, EXPANDING ITS OFFERING FOR BLOOD TESTING MARKET Source text for Eikon: Further company coverage:

Jan 22 2018

BRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase Program

* BIO-RAD AUTHORIZES NEW $250 MILLION SHARE REPURCHASE PROGRAM

Nov 28 2017

Earnings vs. Estimates